Anzeige
Mehr »
Login
Mittwoch, 24.02.2021 Börsentäglich über 12.000 News von 657 internationalen Medien
Breaking News & Strong Buy: Kupferrakete Bam Bam Resources meldet Neuentdeckung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0ESMG ISIN: FR0010259150 Ticker-Symbol: I7G 
Tradegate
23.02.21
16:24 Uhr
70,20 Euro
-0,30
-0,43 %
1-Jahres-Chart
IPSEN SA Chart 1 Jahr
5-Tage-Chart
IPSEN SA 5-Tage-Chart
RealtimeGeldBriefZeit
71,5071,8519:13
71,5571,9519:13

Aktuelle News zur IPSEN Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
IPSEN Aktie jetzt für 0€ handeln
MoIpsen Announces New Data from the Phase II CLARINET FORTE Study Which Demonstrated Preservation of Quality of Life When Increasing Dose Frequencies of Somatuline Autogel (lanreotide)196A total of 9 abstracts presented at the 18th Annual European Neuroendocrine Tumor Society (ENETS) Conference showcasing new data across the patient pathway in neuroendocrine tumors Latest...
► Artikel lesen
12.02.Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital203(In accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers Regulatory News: Ipsen: Market: Euronext...
► Artikel lesen
12.02.Ipsen S.A. (IPSEY) CEO David Loew on Q4 2020 Results - Earnings Call Transcript2
11.02.Ipsen S.A. reports FY results1
11.02.Ipsen S.A.: Ipsen Delivered Sales Growth and Margin Expansion in 2020 - Focused on Executing New Strategy and Delivering Financial Objectives in 2021227Solid full year 2020 results in a COVID-19 environment, with Group sales growth of 3.0%1 and Core Operating margin at 32.0% 2021 guidance of Group sales growth greater than 4.0% at constant...
► Artikel lesen
08.02.Ipsen: New Data From Pivotal Phase III CheckMate -9ER trial of Cabometyx in Combination with Opdivo Showed Significantly Improved QoL Benefits and Sustained Superior Efficacy Versus sunitinib in Patients Living with aRCC1.111With a median follow-up of two years, Cabometyx in combination with Opdivo continues to demonstrate superior progression-free survival, overall survival and objective response rate compared to...
► Artikel lesen
05.02.Ipsen to Showcase Commitment to Going Beyond Traditional Outcome Measures for Patients Living With Renal Cell Carcinoma at ASCO GU 202122110 abstracts to be presented showcasing promising data across multiple genitourinary cancers, including renal cell carcinoma (RCC) and prostate cancer1-11 Highlights include extended follow-up...
► Artikel lesen
20.01.Ipsen Appoints Gwenan White as Executive Vice President, Communications and Public Affairs333Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005966/en/Gwenan White, Executive Vice President, Communications...
► Artikel lesen
19.01.Ipsen: Half-year Statement of IPSEN Liquidity Agreement With NATIXIS ODDO BHF276Regulatory News: Under the liquidity agreement entrusted by IPSEN to NATIXIS ODDO BHF, as of December 31, 2020, the following resources were included to the dedicated liquidity account: 38...
► Artikel lesen
15.01.Ipsen's Dysport shows long duration of response in management of cervical dystonia and spasticity1
15.01.Ipsen: TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport (abobotulinumtoxinA) in five therapeutic indications303Analyses of pivotal study data of Dysport reveal a large proportion of study patients did not require retreatment for at least 12 weeks (and at least 16 weeks for pediatric upper limb spasticity) ...
► Artikel lesen
13.01.Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital228(In accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers Regulatory News: Ipsen Market: Euronext...
► Artikel lesen
04.01.Ipsen China, K-Max achieve strategic cooperation in big health2
23.12.20Broekman übernimmt Belgiengeschäft von Ipsen Logistics: Das niederländische Unternehmen will ...1
09.12.20Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital220(In accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers Regulatory News: Market: Euronext Paris ISIN...
► Artikel lesen
01.12.20Ipsen Issues Mid-term Financial Outlook14
01.12.20Ipsen Highlights New Strategic Priorities and Provides Mid-Term Financial Outlook322Focus on core therapeutic areas of Oncology, Rare Disease and Neuroscience Commitment to invest in R&D supported by SG&A efficiencies Priority on External Innovation strategy to build sustainable...
► Artikel lesen
30.11.20Ipsen Receives FDA Fast Track Designation for Investigational Irinotecan Liposome Injection (ONIVYDE) as a Second-Line Monotherapy Treatment for Small Cell Lung Cancer (SCLC)374Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the United States Food and Drug Administration (FDA) has granted the company Fast Track designation for irinotecan liposome injection...
► Artikel lesen
10.11.20Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital256(In accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers Regulatory News: Ipsen: Market: Euronext...
► Artikel lesen
05.11.20Ipsen taps Synthace to automate drug discovery4
Seite:  Weiter >>
87 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1